You just read:

ViaCyte Receives IND Allowance from FDA and Clearance from Health Canada to Commence International Clinical Trial of PEC-Direct Cell Therapy for High-Risk Type 1 Diabetes

News provided by

ViaCyte, Inc.

May 22, 2017, 09:00 ET